NCT01828086

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 95 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients. This trial never made it to the Phase II part of this trial.

Conditions

• Chronic Plaque-type Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	CJM112	Monoclonal antibody
BIOLOGICAL	Secukinumab	Monoclonal antibody
OTHER	Placebo	Liquid for subcutaneous injection without active drug.

Timeline

• Start date: 2013-06-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2013-04-10
• Last updated: 2020-12-11

Locations

18 sites across 1 country: United States